Lucidin
Lucidin (NSC 30546) is a natural component of madder and can induce mutations in bacterial and mammalian cells.
Product Specifications
CAS Number
[478-08-0]
Product Name Alternative
NSC 30546
UNSPSC
12352005
Hazard Statement
H302, H351
Target
Apoptosis; Caspase; HPV
Type
Natural Products
Related Pathways
Anti-infection; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lucidin.html
Purity
98.03
Solubility
DMSO : 6.67 mg/mL (ultrasonic)
Smiles
O=C1C2=C(C=CC=C2)C(C3=CC(O)=C(CO)C(O)=C13)=O
Molecular Formula
C15H10O5
Molecular Weight
270.24
Precautions
H302, H351
References & Citations
[1]Westendorf J, et al. The genotoxicity of lucidin, a natural component of Rubia tinctorum L., and lucidinethylether, a component of ethanolic Rubia extracts. Cell Biol Toxicol. 1988 Jun;4 (2) :225-39.|[2]Westendorf J, et al. Carcinogenicity and DNA adduct formation observed in ACI rats after long-term treatment with madder root, Rubia tinctorum L. Carcinogenesis. 1998 Dec;19 (12) :2163-8.|[3]Gomes D, et al., Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells. Cancers (Basel) . 2022 Jun 8;14 (12) :2834.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
132600-HRP 100 µL
RIPK2 (Receptor-interacting Serine/Threonine Protein Kinase 2, RIP-like Interacting CLARP Kinase, Receptor-interacting Protein 2, RIP-2, CARD-containing Interleukin-1 beta Converting Enzyme Associated Kinase, CARD-containing IL-1 beta ICE-kinase, RIPK2, CARDIAK, RIP2, UNQ277/PRO314/PRO34092) (HRP)
Ask
View Details